{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T20:55:05Z","timestamp":1792616105172,"version":"4.5.0"},"reference-count":36,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bioorganic Chemistry"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.bioorg.2026.110290","type":"journal-article","created":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T23:02:12Z","timestamp":1784934132000},"page":"110290","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Intravenous pharmacologic ascorbate as a redox modulator and chemosensitizer in targeted Cancer therapies"],"prefix":"10.1016","volume":"181","author":[{"given":"Alberto","family":"Boretti","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bioorg.2026.110290_bb0020","doi-asserted-by":"crossref","DOI":"10.1016\/j.phanu.2020.100190","article-title":"Intravenous vitamin C for reduction of cytokine storms in acute respiratory distress syndrome","volume":"12","author":"Boretti","year":"2020","journal-title":"PharmaNutrition"},{"key":"10.1016\/j.bioorg.2026.110290_bb0025","doi-asserted-by":"crossref","DOI":"10.1016\/j.phanu.2023.100365","article-title":"Intravenous vitamin C against acute respiratory distress syndrome: a narrative review","volume":"27","author":"Boretti","year":"2024","journal-title":"PharmaNutrition"},{"issue":"6","key":"10.1016\/j.bioorg.2026.110290_bb0085","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1093\/jac\/dkh002","article-title":"Vitamin C and SARS coronavirus","volume":"52","author":"Hemil\u00e4","year":"2003","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.bioorg.2026.110290_bb0030","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13046-021-02134-y","article-title":"High-dose intravenous vitamin C, a promising multi-targeting agent in the treatment of cancer","volume":"40","author":"B\u00f6ttger","year":"2021","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"10.1016\/j.bioorg.2026.110290_bb0045","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.3389\/fphys.2018.01182","article-title":"Intravenous vitamin C for cancer therapy\u2014identifying the current gaps in our knowledge","volume":"9","author":"Carr","year":"2018","journal-title":"Front. Physiol."},{"issue":"4","key":"10.1016\/j.bioorg.2026.110290_bb0070","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1177\/1534735414534463","article-title":"Intravenous vitamin C and cancer: a systematic review","volume":"13","author":"Fritz","year":"2014","journal-title":"Integr. Cancer Ther."},{"issue":"4","key":"10.1016\/j.bioorg.2026.110290_bb0095","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0120228","article-title":"High-dose intravenous vitamin C combined with cytotoxic chemotherapy in patients with advanced cancer: a phase I-II clinical trial","volume":"10","author":"Hoffer","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.bioorg.2026.110290_bb0115","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1479-5876-10-189","article-title":"Effect of high-dose intravenous vitamin C on inflammation in cancer patients","volume":"10","author":"Mikirova","year":"2012","journal-title":"J. Transl. Med."},{"issue":"7","key":"10.1016\/j.bioorg.2026.110290_bb0140","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1503\/cmaj.050346","article-title":"Intravenously administered vitamin C as cancer therapy: three cases","volume":"174","author":"Padayatty","year":"2006","journal-title":"CMAJ"},{"issue":"2","key":"10.1016\/j.bioorg.2026.110290_bb0145","article-title":"Intravenous vitamin C as a chemotherapy agent: a report on clinical cases","volume":"23","author":"Riordan","year":"2004","journal-title":"P. R. Health Sci. J."},{"issue":"1","key":"10.1016\/j.bioorg.2026.110290_bb0165","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1111\/ajco.12173","article-title":"Review of high-dose intravenous vitamin C as an anticancer agent","volume":"10","author":"Wilson","year":"2014","journal-title":"Asia Pac. J. Clin. Oncol."},{"issue":"5","key":"10.1016\/j.bioorg.2026.110290_bb0130","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1038\/s41568-019-0135-7","article-title":"Targeting cancer vulnerabilities with high-dose vitamin C","volume":"19","author":"Ngo","year":"2019","journal-title":"Nat. Rev. Cancer"},{"issue":"5","key":"10.1016\/j.bioorg.2026.110290_bb0155","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1016\/j.ccell.2018.07.014","article-title":"Ascorbic acid in cancer treatment: let the phoenix fly","volume":"34","author":"Shenoy","year":"2018","journal-title":"Cancer Cell"},{"issue":"23","key":"10.1016\/j.bioorg.2026.110290_bb0180","doi-asserted-by":"crossref","first-page":"11461","DOI":"10.1021\/acs.chemrev.5c00549","article-title":"Reversible chemistry for Cancer therapy and diagnosis","volume":"125","author":"Xu","year":"2025","journal-title":"Chem. Rev."},{"key":"10.1016\/j.bioorg.2026.110290_bb0170","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2024.116990","article-title":"Coumarin-quinazolinone based photosensitizers: mitochondria and endoplasmic reticulum targeting for enhanced phototherapy via different cell death pathways","volume":"280","author":"Zhao","year":"2024","journal-title":"Eur. J. Med. Chem."},{"issue":"20","key":"10.1016\/j.bioorg.2026.110290_bb0175","doi-asserted-by":"crossref","first-page":"11026","DOI":"10.1039\/C9RA00834A","article-title":"Spermine modified polymeric micelles with pH-sensitive drug release for targeted and enhanced antitumor therapy","volume":"9","author":"Chen","year":"2019","journal-title":"RSC Adv."},{"issue":"21","key":"10.1016\/j.bioorg.2026.110290_bb0050","doi-asserted-by":"crossref","first-page":"8749","DOI":"10.1073\/pnas.0702854104","article-title":"Ascorbate in pharmacologic concentrations selectively generates ascorbate radical and hydrogen peroxide in extracellular fluid in vivo","volume":"104","author":"Chen","year":"2007","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"22","key":"10.1016\/j.bioorg.2026.110290_bb0005","doi-asserted-by":"crossref","first-page":"6590","DOI":"10.1158\/1078-0432.CCR-19-0594","article-title":"First-in-human phase I clinical trial of pharmacologic ascorbate combined with radiation and temozolomide for newly diagnosed glioblastoma","volume":"25","author":"Allen","year":"2019","journal-title":"Clin. Cancer Res."},{"issue":"24","key":"10.1016\/j.bioorg.2026.110290_bb0010","doi-asserted-by":"crossref","first-page":"6838","DOI":"10.1158\/0008-5472.CAN-18-1680","article-title":"Pharmacological ascorbate reduces radiation-induced normal tissue toxicity and enhances tumor radiosensitization in pancreatic cancer","volume":"78","author":"Alexander","year":"2018","journal-title":"Cancer Res."},{"key":"10.1016\/j.bioorg.2026.110290_bb0075","article-title":"Pharmacological ascorbate improves the response to platinum-based chemotherapy in advanced stage non-small cell lung cancer","volume":"53, Article 102318","author":"Furqan","year":"2022","journal-title":"Redox Biol."},{"issue":"4","key":"10.1016\/j.bioorg.2026.110290_bb0150","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1016\/j.ccell.2017.02.018","article-title":"O2(\u2212) and H2O2-mediated disruption of Fe metabolism causes the differential susceptibility of NSCLC and GBM cancer cells to pharmacological ascorbate","volume":"31","author":"Schoenfeld","year":"2017","journal-title":"Cancer Cell"},{"issue":"3","key":"10.1016\/j.bioorg.2026.110290_bb0160","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1007\/s00280-013-2070-8","article-title":"Pharmacological ascorbate with gemcitabine for the control of metastatic and node-positive pancreatic cancer (PACMAN): results from a phase I clinical trial","volume":"71","author":"Welsh","year":"2013","journal-title":"Cancer Chemother. Pharmacol."},{"issue":"4","key":"10.1016\/j.bioorg.2026.110290_bb0060","doi-asserted-by":"crossref","DOI":"10.3390\/antiox10040614","article-title":"Catalase modulates the radio-sensitization of pancreatic cancer cells by pharmacological ascorbate","volume":"10","author":"Du","year":"2021","journal-title":"Antioxidants"},{"issue":"2","key":"10.1016\/j.bioorg.2026.110290_bb0065","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1158\/1078-0432.CCR-09-1713","article-title":"Mechanisms of ascorbate-induced cytotoxicity in pancreatic cancer","volume":"16","author":"Du","year":"2010","journal-title":"Clin. Cancer Res."},{"issue":"4","key":"10.1016\/j.bioorg.2026.110290_bb0035","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1016\/j.ijrobp.2022.10.012","article-title":"Manipulation of redox metabolism using pharmacologic ascorbate opens a therapeutic window for radio-sensitization by ATM inhibitors in colorectal cancer","volume":"115","author":"Callaghan","year":"2023","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"10.1016\/j.bioorg.2026.110290_bb0055","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1016\/j.redox.2016.10.010","article-title":"Tumor cells have decreased ability to metabolize H2O2: implications for pharmacological ascorbate in cancer therapy","volume":"10","author":"Doskey","year":"2016","journal-title":"Redox Biol."},{"issue":"3","key":"10.1016\/j.bioorg.2026.110290_bb0135","doi-asserted-by":"crossref","first-page":"154","DOI":"10.3109\/10715762.2012.755263","article-title":"Inhibitors of hydroperoxide metabolism enhance ascorbate-induced cytotoxicity","volume":"47","author":"Olney","year":"2013","journal-title":"Free Radic. Res."},{"key":"10.1016\/j.bioorg.2026.110290_bb0015","doi-asserted-by":"crossref","DOI":"10.1016\/j.redox.2024.103375","article-title":"A randomized trial of pharmacological ascorbate, gemcitabine, and nab-paclitaxel for metastatic pancreatic cancer","volume":"77","author":"Bodeker","year":"2024","journal-title":"Redox Biol."},{"issue":"32","key":"10.1016\/j.bioorg.2026.110290_bb0105","doi-asserted-by":"crossref","first-page":"4698","DOI":"10.3748\/wjg.v28.i32.4698","article-title":"International patterns in incidence and mortality trends of pancreatic cancer in the last three decades: a joinpoint regression analysis","volume":"28","author":"Ilic","year":"2022","journal-title":"World J. Gastroenterol."},{"issue":"8","key":"10.1016\/j.bioorg.2026.110290_bb0080","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.1016\/j.cell.2023.02.014","article-title":"Pancreatic cancer: advances and challenges","volume":"186","author":"Halbrook","year":"2023","journal-title":"Cell"},{"issue":"23","key":"10.1016\/j.bioorg.2026.110290_bb0090","doi-asserted-by":"crossref","first-page":"6287","DOI":"10.1158\/1078-0432.CCR-18-0900","article-title":"Immunotherapy in pancreatic adenocarcinoma: beyond \u201ccopy\/paste\u201d","volume":"27","author":"Hester","year":"2021","journal-title":"Clin. Cancer Res."},{"issue":"1","key":"10.1016\/j.bioorg.2026.110290_bb0125","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0029794","article-title":"Phase I evaluation of intravenous ascorbic acid in combination with gemcitabine and erlotinib in patients with metastatic pancreatic cancer","volume":"7","author":"Monti","year":"2012","journal-title":"PLoS One"},{"issue":"3","key":"10.1016\/j.bioorg.2026.110290_bb0100","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1016\/j.annonc.2021.12.002","article-title":"The ECHELON-2 trial: 5-year results of a randomized, phase III study of brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma","volume":"33","author":"Horwitz","year":"2022","journal-title":"Ann. Oncol."},{"issue":"2","key":"10.1016\/j.bioorg.2026.110290_bb0040","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1158\/0008-5472.CAN-09-1947","article-title":"Drug combination studies and their synergy quantification using the Chou-Talalay method","volume":"70","author":"Chou","year":"2010","journal-title":"Cancer Res."},{"issue":"11","key":"10.1016\/j.bioorg.2026.110290_bb0110","doi-asserted-by":"crossref","first-page":"2608","DOI":"10.3390\/cancers14112608","article-title":"Repurposing vitamin C for cancer treatment: focus on targeting the tumor microenvironment","volume":"14","author":"Li","year":"2022","journal-title":"Cancers"},{"key":"10.1016\/j.bioorg.2026.110290_bb0120","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1479-5876-11-191","article-title":"Clinical experience with intravenous administration of ascorbic acid: achievable levels in blood for different states of inflammation and disease in cancer patients","volume":"11","author":"Mikirova","year":"2013","journal-title":"J. Transl. Med."}],"container-title":["Bioorganic Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0045206826008266?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0045206826008266?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T21:06:37Z","timestamp":1791407197000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0045206826008266"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":36,"alternative-id":["S0045206826008266"],"URL":"https:\/\/doi.org\/10.1016\/j.bioorg.2026.110290","relation":{},"ISSN":["0045-2068"],"issn-type":[{"value":"0045-2068","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Intravenous pharmacologic ascorbate as a redox modulator and chemosensitizer in targeted Cancer therapies","name":"articletitle","label":"Article Title"},{"value":"Bioorganic Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bioorg.2026.110290","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"110290"}}